The type dimension of the Microbial Contamination Identification market is divided into culture‑based methods, molecular techniques, immunoassays, biosensors, and rapid‑test kits. Culture‑based methods, while labor‑intensive, still account for a sizable share because of regulatory mandates in legacy facilities; they contribute roughly 20 % of total revenue. Molecular techniques—principally polymerase chain reaction (PCR), quantitative PCR, and next‑generation sequencing—drive the fastest growth, reflecting a shift toward faster turnaround and higher specificity, and they represent about 40 % of market value. Immunoassays, including enzyme‑linked immunosorbent assay (ELISA) formats, occupy near 15 % as they balance speed with moderate sensitivity. Biosensor platforms, leveraging electrochemical or optical transduction, are emerging with a 12 % share, supported by integration with IoT data pipelines. Finally, rapid‑test kits, often lateral‑flow formats, hold roughly 13 % of the market, favored for on‑site screening where laboratory infrastructure is limited. Collectively, these type segments delineate the market’s revenue architecture and guide investment priorities.